Gary Ingenito - Sep 14, 2022 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Chief Medical & Reg. Officer
Signature
/s/ Gary Ingenito
Stock symbol
CPRX
Transactions as of
Sep 14, 2022
Transactions value $
-$1,612,589
Form type
4
Date filed
9/16/2022, 05:00 PM
Previous filing
Jun 23, 2022
Next filing
Dec 8, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common stock, par value $0.001 per share Options Exercise $221K +55K +249.4% $4.01 77.1K Sep 14, 2022 Direct
transaction CPRX Common stock, par value $0.001 per share Sale -$861K -55K -71.38% $15.65 22.1K Sep 14, 2022 Direct F1, F2
transaction CPRX Common stock, par value $0.001 per share Options Exercise $408K +88K +399.04% $4.64 110K Sep 14, 2022 Direct
transaction CPRX Common stock, par value $0.001 per share Sale -$1.38M -88K -79.96% $15.69 22.1K Sep 14, 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Options to purchase common stock Options Exercise $0 -55K -5.13% $0.00 1.02M Sep 14, 2022 Common Stock 55K $4.01 Direct F4
transaction CPRX Options to purchase common stock Options Exercise $0 -88K -8.66% $0.00 929K Sep 14, 2022 Common Stock 88K $4.64 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Dr. Ingenito sold the shares on the open market for personal reasons and not as a result of any disagreement with the Registrant. Dr. Ingenito remains an officer of the Company.
F2 Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $15.56 to $15.80 per share.
F3 Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $15.62 to $15.79 per share.
F4 Options vested in three annual tranches beginning on January 2, 2018.
F5 Options vested in two annual tranches beginning on December 2, 2020.